L13: Thrombotic disorders Flashcards

1
Q

Virchows triad

A

RISK FACTORS OF THROMBOSIS

  1. Vascular injury (blood vessels)
    - Trauma
    - Surgical manipulation
    - Prior thrombosis
    - Atherosclerosis
  2. Stasis (flow of blood) (mainly venous)
    - Immobility (post-op, coma, debility, flights)
    - Pressure (catheter, tumour)
    - Increased viscosity (polycythemia, dehydration, EPO)
  3. Blood hypercoagulability (mainly venous)
    - Increased procoagulants
    - Decrease in inhibitors
    - Impaired fibrinolysis (rare)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

DVT - incidence

A
  • 1/1000 per year
  • Incidence increases with age (much greater over 80)
  • Very rare in children (usually only sick)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

DVT presentation and sequelae

A

Clot of red cells and fibrin usually in proximal leg vein -> block upward flow of blood

  • Leg swelling, pitting oedema
  • Venous discolouration (engorgement)
  • Leg pain

Sequelae:

  • Often clot breaks off -> pulmonary embolism
  • If untreated, 50% will embolise
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Pulmonary embolism

A
  • 1/2000 people per year (5% fatal)
  • Clot in deep vein breaks off and eventually becomes lodged in pulmonary arteries or if large in pulmonary trunk
  • If pulmonary trunk obstructed very serious (right side of heart blow out)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Diagnosis of PE

A

Presentation:

  • Classic triad: pleuritic pain, SOB, haemoptysis
  • Tachycardia
  • Tachypnoea
  • Hypoxia

Testing:

  • D-dimer (usually positive)
  • CT pulmonary angiogram
  • V/Q scan (ventilation normal but perfusion decreased)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Algorithm for DVT and PE

A
  • Symptoms are non-specific and common
  • Algorithm to stratify groups for further testing
    Well’s score for DVT:
  • If high probability –> doppler US
  • If low probability –> D-dimer testing (neg -> discharge, pos -> doppler US)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

D-dimer testing

A
  • Measures products of fibrin breakdown
  • Positive in 83-98% of DVT, PE
  • Also positive in patients without VTE e.g. inflammation, surgery, trauma
  • High negative predictive value, low positive predictive value
  • Should be interpreted with clinical score
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Massive PE

A
  • Sudden death (15% of these)
  • > 50% mortality
  • Hypotension = defining feature
  • Severe right heart strain due to back pressure from pulmonary arteries
  • Require thrombolysis - given TPA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Thrombophilia

A
  • Tendency to develop thrombosis
  • Acquired and/or inherited (usually referring to hereditary)
  • Manifest as VTE
  • Multi-hit theory
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Causes of VTE

A

30-40 % spontaneous (~50% of these have thrombophilia)

Rest are provoked events:

  • Surgery/trauma
  • Immobility
  • Hospitalisation
  • Malignancy (up to 20%)
  • Hormonal replacement therapy/OCP/pregnancy
  • Other (Myeloproliferative disease, anti-phopholipid syndrome)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Inherited thrombophilia causes

A
  1. Abnormal inhibitor function: resistance to activated protein C (mutant factor V Leiden)
  2. Deficiency of inhibitors: antithrombin, protein C, protein S (rare but antithrombin deficiency is high risk for future thrombosis)
  3. Increased factor levels: prothrombin gene mutation 20210A or elevated factor VIII
  4. (Dysfibrinogenemia - rare)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Factor V Leiden

A
  • Single point mutation in factor V
  • Most common hereditary cause of thrombophilia

Normally: Va enhances X activation
- Activated protein C cleaves normal Va -> slows Xa production

Factor V Leiden: activated protein C unable to cleave factor V Leiden
- Xa activation continues, Va levels 20% higher = mild tendency to thrombosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Why test for activated protein C resistance?

A

Heterozygote: 3-7 fold increased risk of thrombosis
Homozygous: 50-100 fold increased risk of thrombosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Thrombophilia testing

A
  • Measure factor V Leiden and prothrombin gene mutation (most common)
  • Also measure natural inhibitors
  • Anti-thrombin, protein C and S deficiencies more severe –> only situation where management changed
  • Testing usually only for young people with spontaneous VTE
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Heparin

A
  • Inhibitor through increased antithrombin effect –> inactivation of Xa and IIa)
  • Given initially, immediate effect
  • APTT 1+1 prolonged, TCT markedly prolonged
  • Reversed (lab and clinically) by protamine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

LMWH

A

= low molecular weight heparin

  • Similar to IV heparin but smaller chains
  • Increased antithrombin effect (inhibits Xa)
  • Subcutaneous with better bioavailability
  • E.g. enoxaparin 1mg/kg twice daily
  • Weight based dose
17
Q

Warfarin

A
  • Inhibits recycling of vit k –> factors II, VII, IX and X lack carboxylation –> reduced production
  • Monitored with INR (therapeutic range 2-3)
  • High INR = increased bleeding risk
  • Interacts with many drugs: antibiotics, anticonvulsants, amiodarone, diltiazem, citalopram etc
  • Lag between starting drug and effect due to vit K stores (5-7 days to therapeutic level)
18
Q

Reversal of warfarin

A
  • Vit K IV takes 12-24hrs (synthesis of clotting factors)
  • Prothrombinex (gives factor II, IX, X)
  • FPP not recommended (requires too much)
19
Q

DOACs

A

= direct acting oral anticoagulants

  • Direct inhibitors of activated clotting factors
  • Half life 9-14hrs
  • Rivaroxaban (Xa) and dabigatran (IIa) same as warfarin for treatment of VTE
  • Better than warfarin for treatment of AF (better stroke prevention with similar rates of bleeding)
20
Q

DOACs advantages and disadvantages

A

Advantages:

  • No monitoring needed, fixed dose
  • Less intracranial haemorrhage (compared to warfarin)

Disadvantages:
- Renal excretion (esp. dabigatran) so retained in renal impairment

21
Q

DOACs and clotting tests

A

Dabigatran: (inhibits IIa)

  • TCT extremely sensitive
  • APTT prolonged at therapeutic levels (1+1)
  • PR prolonged if very high
  • Antidote: idarucizumab (immediate reversal, may rebound in 24-48hrs if levels high or renal impairment)

Rivaroxaban: (inhibits Xa)

  • PR prolonged to some extend, APTT less so
  • Antidote in development (prothrombin sometimes used)
22
Q

Morbidity rates in DVT and PE

A

Up to 30% of DVT patients develop post-thrombotic syndrome

  • Pain, swelling/oedema, redness, venous eczema, ulceration
  • Graduated compression stockings may help symptoms

2% of PE patients may develop chronic thromboembolic pulmonary hypertension
- SOBOE, dizziness, fatigue